What is the P/E ratio of Royalty Pharma plc (RPRX)?

The trailing price-to-earnings (P/E) ratio of Royalty Pharma plc is 29.3.

Does Royalty Pharma plc (RPRX) pay a dividend?

Yes, Royalty Pharma plc pays an annual dividend of 0.94 USD, yielding 1.69%.

Are RPRX dividends eligible for the Canadian dividend tax credit?

No. Royalty Pharma plc is a US company; its dividends are subject to 15% US withholding tax when held in non-registered or TFSA accounts. In an RRSP, no withholding applies.

What is the market capitalization of Royalty Pharma plc?

Royalty Pharma plc (RPRX) has a market capitalization of approximately 24,366,777,497 USD.

How many ETFs hold RPRX?

RPRX is held by 6 ETFs tracked on Investir en Bourse.

Where can I buy RPRX in Canada?

RPRX can be purchased through any Canadian online broker including Wealthsimple, Questrade, Qtrade, or RBC Direct Investing.

RPRX

Royalty Pharma plc

Royalty Pharma plc (RPRX) is an American company in the healthcare sector, listed on NASDAQ. Market capitalization of 24.4 billion USD (large-cap).

Details

Price54.97 USD

Market cap24.37 G USD

Dividend yield1.69%

Annual rate0.94 USD

Payout ratio47.11%

Next ex-dateMay 15, 2026

ROE13.77%

Debt / Equity90.32%

SectorHealthcare

Websiteroyaltypharma.com

Updated 1h ago

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.